11.1 Information on toxicological effects
Acute toxicity
Oral: No data available
LC50 Inhalation - 4 h - 0,501 mg/l - dust/mist
Dermal: No data available
Skin corrosion/irritation
Remarks: No data available
Serious eye damage/eye irritation
Remarks: No data available
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
11.2 Additional Information
Endocrine disrupting properties
Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
Symptoms of systemic copper poisoning may include: capillary damage, headache, cold sweat, weak pulse, and kidney and liver damage, central nervous system excitation followed by depression, jaundice, convulsions, paralysis, and coma. Death may occur from shock or renal failure. Chronic copper poisoning is typified by hepatic cirrhosis, brain damage and demyelination, kidney defects, and copper deposition in the cornea as exemplified by humans with Wilson's disease. It has also been reported that copper poisoning has lead to hemolytic anemia and accelerates arteriosclerosis., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.